Trial Profile
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms IPS-BOOSTER
- 24 Feb 2021 Status changed from active, no longer recruiting to completed.
- 12 Dec 2018 New trial record